

BIOMATLANTE joins the AMS Group

Nantes, France, 2 December 2019.

Biomatlante is very pleased to announce the acquisition of 100% of its shares by Advanced Medical Solutions Group plc (London Alternative Investment Market: AMS).

The acquisition will strengthen AMS's product portfolio, R&D pipeline, and market access. It provides the Group with a range of revenue-generating surgical products and an R&D pipeline of complementary biosurgical technologies and offers significant growth potential in additional surgical markets estimated to be worth \$0.5 billion.

Biomatlante platform technologies will broaden the Group's biosurgical technology offering while also offering multiple synergies across the sales, marketing, regulatory, operational divisions and R&D.

Commenting this acquisition, Chantal Gobin-Daculsi, Co-founder and President of Biomatlante said: *"This is an important strategic step for Biomatlante and we are excited to become part of the AMS group. AMS is a high-quality global Company with the scale, expertise and track record of realising the value of scientific innovation and rapidly growing the sales of marketed products. As now part of the AMS family, the know-how of our team can be fully realised to pursue Biomatlante's continued growth in innovative bone regenerative technologies."*

Julien Dert, CEO of Biomatlante, added: *"We are very pleased that Biomatlante has found a strong partner like AMS to pursue its development. All Biomatlante team, including its Co-founder Dr Guy Daculsi who will continue as our Scientific Advisor, is very enthusiastic and ready to drive the synthetic bone graft market forward."*

Commenting on the acquisition, Chris Meredith, CEO of AMS, said: *"This acquisition is in line with our strategy to acquire technologies that are complementary to our surgical portfolio and allow us to leverage our global routes to market. The acquisition grants AMS access to multiple new markets, including the synthetic bone substitutes market which is estimated at \$0.5 billion. We are excited to welcome the Biomatlante team to AMS and look forward to working together with them to accelerate the commercial success internationally and to continue to develop the Biomatlante technology in a wide range of potential applications and indications."*

About Biomatlante, experts in bone regeneration

Based near Nantes, Western France, Biomatlante specializes, as a world leader, in synthetic bone regenerative technologies, in orthopedic, traumatological, spine and dental applications. It markets its innovative products in more than 50 countries worldwide. Biomatlante prides itself on staying abreast of an ever-evolving market, thus ensuring its products meet the demanding requirements of surgeons and healthcare companies around the globe.

Thanks to a robust research and development department, Biomatlante has been granted various patents and licenses covering both biomaterials and new associated technologies, based on its MBPCP® Proprietary Technology.

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group acquired Sealantis, an Israeli-based medical device company with a patent-protected internal sealant technology platform.

AMS's products, manufactured in the UK, the Netherlands, Germany, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK and Germany, as well as the recently acquired R&D facility in Israel. Established in 1991, the Group has approximately 650 employees. For more information please see www.admedsol.com.

For further information, write to us at contact@biomatlante.com.